UTHR
United Therapeutics Corporation · Healthcare · Biotechnology
Momentum-Eingaben (vergleichbare Manager): Halterbreite 0.0% · Aktienfluss -2.9% · neue Nettopositionen -4.8% — Formel
Alle Eigentumszahlen: nur beobachtete 13F-Manager, Stammaktienpositionen, Berichtszeitraum Q3 2025
| Quartal | Inhaber | Δ | Aktien | Gemeldeter Wert | Neu | Ausstiege |
|---|---|---|---|---|---|---|
| Q2 2026 | 159 | +4 | 28.20M | $15.29B | +8 | −3 |
| Q1 2026 | 157 | -1 | 29.64M | $17.54B | +5 | −7 |
| Q4 2025 | 157 | +1 | 32.29M | $15.72B | +2 | — |
| Q3 2025 | 21 | 0 | 20.11M | $8.43B | +1 | −2 |
| Q2 2025 | 19 | 0 | 20.17M | $5.79B | — | — |
| Q1 2025 | 16 | +1 | 10.14M | $3.12B | +1 | — |
| Q4 2024 | 15 | 0 | 10.52M | $3.71B | +1 | −1 |
| Q3 2024 | 14 | 0 | 8.99M | $3.22B | — | — |
| Q2 2024 | 14 | — | 8.17M | $2.60B | — | — |
| # | Manager | Aktien | Δ Anteile | Wert | Deren Gewichtung | Gehalten | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passiv) | 5.35M | +0.4% | $2.24B | 0.0% | ▲ Add | 2 | SEC ↗ ×22 |
| 2 | The Vanguard Group ✦ (passiv) | 4.42M | -0.7% | $1.85B | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 3 | Renaissance Technologies ✦ | 2.17M | +2.6% | $911.11M | 1.2% | ▲ Add | 6 | SEC ↗ |
| 4 | State Street Global Advisors ✦ (passiv) | 1.92M | -11.3% | $805.98M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 5 | Wellington Management ✦ | 1.40M | -3.1% | $586.38M | 0.1% | ▼ Trim | 6 | SEC ↗ ×7 |
| 6 | Geode Capital Management ✦ (passiv) | 1.25M | +4.1% | $522.91M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | AQR Capital Management ✦ | 986.48K | -22.5% | $413.54M | 0.3% | ▼ Trim | 6 | SEC ↗ ×4 |
| 8 | JPMorgan Chase ✦ | 495.87K | — | $207.88M | 0.0% | n/c | 1 | SEC ↗ ×28 |
| 9 | Morgan Stanley ✦ | 438.80K | — | $183.95M | 0.0% | n/c | 1 | SEC ↗ ×12 |
| 10 | T. Rowe Price ✦ | 300.93K | +162.8% | $126.15M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 11 | Citadel Advisors ✦ | 273.98K | +94.3% | $114.86M | 0.1% | ▲ Add | 4 | SEC ↗ ×2 |
| 12 | Millennium Management ✦ | 258.58K | +235.5% | $108.40M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 13 | Fidelity (FMR) ✦ | 250.33K | -41.0% | $104.94M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 14 | Arrowstreet Capital ✦ | 208.53K | -38.5% | $87.42M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 15 | Point72 Asset Management ✦ | 99.78K | Neu | $41.83M | 0.1% | New | 1 | SEC ↗ |
| 16 | Goldman Sachs Group ✦ | 81.54K | — | $34.18M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 17 | Gotham Asset Management ✦ | 80.96K | -9.4% | $33.94M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 18 | D. E. Shaw & Co. ✦ | 64.71K | +199.5% | $27.13M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 19 | Fisher Asset Management ✦ | 23.58K | +26.8% | $9.89M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 20 | Two Sigma Investments ✦ | 16.09K | +82.8% | $6.75M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 21 | Bridgewater Associates ✦ | 16.07K | -91.8% | $6.73M | 0.0% | ▼ Trim | 6 | SEC ↗ |
„Ihre Gewichtung" = Anteil der Position am gemeldeten 13F-Eigenkapitalwert des jeweiligen Managers — das Conviction-Maß. ✦ = kuratorisch ausgewählter Manager.
Neue Käufer
| Point72 Asset Management | $41.83M | 0.1% |
Ausgestiegen
| Norges Bank | $136.45M | war 0.0% |
| Marshall Wace | $79.45M | war 0.1% |
Marktweiter Kontext: über ALLE 13F-Melder (strukturierte SEC-Daten, Q1 2026): 844 Inhaber, 41.22M Anteile, $23.10B gemeldet. Dies ist ein anderer, älterer Zeitraum als die oben genannten Zahlen des erfassten Universums; beide werden niemals vermischt.
Was die erfassten Halter dieses Wertpapiers am häufigsten sonst noch halten — Zählungen gemeinsamer Eigentümerschaft, keine fundamentalen Zusammenhänge.
Käufe auf dem offenen Markt (P)
Keine Insider-Käufe auf dem offenen Markt in unserem Erfassungszeitraum.
Verkäufe auf dem offenen Markt (S)
Officer, Director · 800 Ant. · $426,689
Officer, Director · 40 Ant. · $21,649
Officer, Director · 200 Ant. · $105,725
Officer, Director · 200 Ant. · $105,099
Officer, Director · 824 Ant. · $442,164
Officer, Director · 600 Ant. · $319,244
Officer, Director · 767 Ant. · $403,951
Officer, Director · 1.09K Ant. · $588,682
Officer, Director · 199 Ant. · $105,497
Officer, Director · 605 Ant. · $325,853
Zuteilungen, Ausübungen und Steuereinbehalte werden hier nie als Käufe oder Verkäufe gezählt. Methodik